

137. Novelli EM, Moon CH, Pham TA, Perkins LA, Little-Ihrig, L, Tavakoli S, Mason NS, Lang L, Chen X, Laymon CM, Gladwin MT, **Anderson CJ**. First report of <sup>68</sup>Ga-PRGD2 PET/MRI molecular imaging of vaso-occlusion in a patient with sickle cell disease. *BJR Case Reports*, 6: 20200024
138. Perkins LA<sup>#</sup>, Nyiranshuti L<sup>#</sup>, Little-Ihrig L, Latoche JD, Day KE, Zhu Q, Tavakoli S, Sundd P, Novelli EM\*, **Anderson CJ\***. (<sup>#</sup>co-first authors; \*co-corresponding authors). Integrin VLA-4 as a PET imaging biomarker of hyper-adhesion in transgenic sickle mice. *Blood Advances*, 2020; 4:4102-4112.
140. Chen Q, Yu J, Lukashova L, Latoche J, Zhu J, Lavery L, Verdelis K, **Anderson CJ**, Kim K. Validation of ultrasound super-resolution imaging of vasa vasorum in rabbit atherosclerotic plaques. *Transactions on Ultrasonics, Ferroelectrics and Frequency Control*; 2020; 67:1725-1729.
141. Haddad J, Latoche JD, Nigam S, Bellavia MC, Day KE, Zhu Q, Edwards WB, **Anderson CJ**, Tavakoli, S. Molecular imaging of very late antigen-4 (VLA-4) in acute lung injury. *Journal of Nuclear Medicine*, 2021; 62:280-286.
141. Dai L, Zhang J, Wong CT, Chan WTK, Ling X, **Anderson CJ**, Law G-L. Design of Functional Chiral Cyclen-based Radiometal Chelators for Theranostics. *Inorganic Chemistry* 2021; 60:7082-7088.
142. Mattila J, Beaino W, White AG, Nyiranshuti L, Maello PA, Tomko J, Frye J, Fillmore D, Scanga CA, Lin, PL, Flynn JL, **Anderson CJ**. Retention of (<sup>64</sup>)Cu-FLFLF, a Formyl Peptide Receptor 1-Specific PET Probe, Correlates with Macrophage and Neutrophil Abundance in Lung Granulomas from Cynomolgus Macaques. *ACS Infectious Disease*; 2021; 7:2264-2276; DOI: 10.1021/acsinfecdis.0c00826.
143. Foster A, Nigam S, Tatum DS, Raphael I, Xu J, Kumar R, Plakseychuk E, Latoche JD, Vincze S, Li B, Giri R, McCarl LH, Edinger R, Ak M, Peddagangireddy V, Foley LM, Hitchens TK, Colen RR, Pollack IF, Panigrahy A, Magda D\*, **Anderson CJ\***, Edwards WB\*, Kohanbash G\*. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumor-infiltrating immune cells in glioma. *EBioMedicine*, 2021; 17:103571. (\*co-corresponding authors)
144. Bellavia MC, Nyiranshuti L, Latoche JD, Ho K-V, Fecek RJ, Taylor JL, Day KE, Nigam S, Pun M, Gallazzi F, Edinger RS, Storkus WJ, Patel RB\*, **Anderson CJ\***. PET imaging of VLA-4 in a new BRAF<sup>V600E</sup> mouse model of melanoma. *Molecular Imaging and Biology*; 2022; 24:425-433; DOI 10.1007/s11307-021-01666-1. (\*co-corresponding authors)
145. Mandell JB, Douglas N, Ukani V, Beumer JH, Guo J, Payne J, Newman R, Mancinelli L, Intini G, **Anderson CJ**, Watters R, Weiss K. *ALDH1A1* gene expression and cellular copper levels between low and highly metastatic osteosarcoma provide a case for novel repurposing with disulfiram and copper. *Sarcoma*, 2022; 2022:7157507.
146. Kankanamalage PHA, Hoerres R, Ho K-V, **Anderson CJ**, Gallazzi F, Hennkens HM. *p*-NCS-Bn-NODAGA as a bifunctional chelator for radiolabeling with the <sup>186</sup>Re/<sup>99m</sup>Tc-tricarbonyl core: Radiochemistry with model complexes and a GRPR-targeting peptide. *Nuclear Medicine and Biology*, 2022; 108-109:1-9.

147. Olatunji FP, Pun M, Herman JW, Romero O, Maniatopoulos M, Latoche JD, Parise RA, Guo J, Beumer JH, **Anderson CJ\***, Berkman CE\*. Modular Smart Molecules for PSMA-Targeted Chemotherapy. *Molecular Cancer Therapeutics*, Published on-line August 23, 2022; <https://doi.org/10.1158/1535-7163.MCT-22-0160>.
147. Mannes PZ, Barnes CE, Biermann J, Latoche JD, Day KE, Zhu Q, Tabary M, Xiong Z, Nedrow JR, Izar B, **Anderson CJ**, Villanueva FS, Lee JS, Tavakoli S. Molecular imaging of chemokine-like receptor 1 (CMKLR1) in experimental acute lung injury. *Proceedings of the National Academy of Sciences* 2023; 120 (3) e2216458120. <https://doi.org/10.1073/pnas.2216458120>
148. Zhu Q, Barnes CE, Mannes PZ, Latoche JD, Day KE, Nedrow JR, Novelli EM, **Anderson CJ**, Tavakoli S. Targeted Imaging of Very Late Antigen-4 for Noninvasive Assessment of Lung Inflammation-Fibrosis Axis. *European Journal of Nuclear Medicine and Molecular Imaging Research*, 2023; 13:55. <https://doi.org/10.1186/s13550-023-01006-0>
149. Nisboym M, Vincze SR, Xiong Z, Sneiderman CT, Raphael RA, Sever RE, Li B, Jaswal AP, Day KE, Latoche JD, Foley LM, Karimi H, Hitchens KT, Agnihotri S, Hu B, Rajasunderam D, **Anderson CJ**, Blumenthal DT, Pearce TM, Uttam S, Nedrow JR, Panigrahy A, Pollack IF, Lieberman FS, Drappatz J, Raphael I\*, Edwards WB\*, Kohanbash G\*. Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival following Immunotherapy in Murine GBM. *Cancer Research Communications* 2023; 3:1173-1188; <https://doi.org/10.1158/2767-9764.CRC-22-0434>.
150. Pun MD, Gallazzi F, Ho K-V, Watkinson L, Carmack TL, Iweha E, Li L, **Anderson CJ\***. Albumin-binding Lutetium-177 LLP2A Derivatives as Theranostics for Melanoma. *Molecular Pharmaceutics* 2024; 21:2960-2969. <https://doi.org/10.1021/acs.molpharmaceut.4c00095>.
151. Rachedi NS, Tang Y, Tai Y-Y, Zhao J, Chauvet C, Grynblat J, Akoumia KKF, Estephan L, Torrino S, Sbaji C, Ait-Mouffok A, Latoche JD, Al Aaraj Y, Brau F, Abelanet S, Clavel, Zhang Y, Guillemier C, Kumar NVG, Tavakoli S, Mercier O, Risbano MG, Yao Z-K, Yang G, Ouerfelli O, Lewis JS, Montani D, Humbert M, Steinhauser ML, **Anderson CJ**, Oldham WS, Peros F, Bertero T, Chan SY. Dietary intake and glutamine-serine metabolism control pathological vascular stiffness. *Cell Metabolism* 2024; 36:1335-1350 e8. <https://doi.org/10.1016/j.cmet.2024.04.010>
152. Lewis MR, Schaedler AW, Ho K-V, Golzy M, Mathur A, Pun M, Gallazzi F, Watkinson LD, Carmack TL, **Anderson CJ**, Smith CJ. Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen. *Nuclear Medicine and Biology*, 2024; 136-137: 108938. <https://doi.org/10.1016/j.nucmedbio.2024.108938>
153. Ho K-V, Tatum DS, Watkinson L, Carmack TL, Jia F, Mascioni A, Maitz CA, Magda DM, **Anderson CJ\***. Single chelator-minibody theranostic agents for Zr-89 PET imaging and Lu-177 radiopharmaceutical therapy of PSMA-expressing prostate cancer. *Journal of Nuclear Medicine*, 2024; 65:1435-1442, DOI: <https://doi.org/10.2967/jnumed.124.267667>